本文選題：急性冠狀動脈綜合征 + 替格瑞洛��； 參考：《中國新藥與臨床雜志》2016年09期

【摘要】：替格瑞洛是一種新型的具有多效性的P_2Y_(12)受體抑制劑,能夠抑制腺苷二磷酸誘導(dǎo)的血小板聚集。目前的研究發(fā)現(xiàn)替格瑞洛還能影響腺苷的濃度,其可能的機制是通過抑制平衡型核苷轉(zhuǎn)運體1來抑制紅細胞對腺苷的攝取,增加胞外腺苷濃度。相關(guān)的研究提示,在使用替格瑞洛時,呼吸困難、心動過緩等不良反應(yīng)的發(fā)生也與腺苷濃度的增加相關(guān)。本文將對替格瑞洛對腺苷濃度的影響以及所引起的生物學(xué)效應(yīng)和不良反應(yīng)進行綜述。
[Abstract]:Tigrilol is a novel multipotent PSP 2 Y12 receptor inhibitor which can inhibit platelet aggregation induced by adenosine diphosphate (ADP). It has been found that tigrilol can also affect the concentration of adenosine by inhibiting the uptake of adenosine in erythrocytes and increasing the concentration of extracellular adenosine by inhibiting balanced nucleoside transporter 1. Related studies suggest that adverse reactions such as dyspnea and bradycardia are also associated with increased adenosine concentration in tigrillo. This article reviews the effects of tigrilol on adenosine concentration, biological effects and adverse reactions.
【作者單位】： 復(fù)旦大學(xué)附屬中山醫(yī)院藥劑科;
【分類號】：R973.2
，

本文編號：2086756